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Abstract
Canine hemangiosarcoma is a highly aggressive vascular neoplasm associated with extensive 
clinical and anatomical heterogeneity and a grave prognosis. Comprehensive molecular 
characterization of hemangiosarcoma may identify novel therapeutic targets and advanced clinical 
management strategies, but there are no published reports of tumor-associated genome instability 
and disrupted gene dosage in this cancer. We performed genome-wide microarray-based somatic 
DNA copy number profiling of 75 primary intra-abdominal hemangiosarcomas from five popular 
dog breeds that are highly predisposed to this disease. The cohort exhibited limited global 
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genomic instability, compared to other canine sarcomas studied to date, and DNA copy number 
aberrations (CNAs) were predominantly of low amplitude. Recurrent imbalances of several key 
cancer-associated genes were evident; however the global penetrance of any single CNA was low 
and no distinct hallmark aberrations were evident. Copy number gains of dog chromosomes 13, 24 
and 31, and loss of chromosome 16, were the most recurrent CNAs involving large chromosome 
regions, but their relative distribution within and between cases suggests they most likely represent 
passenger aberrations. CNAs involving CDKN2A, VEGFA and the SKI oncogene were identified 
as potential driver aberrations of hemangiosarcoma development, highlighting potential targets for 
therapeutic modulation. CNA profiles were broadly conserved between the five breeds, although 
subregional variation was evident, including a near two-fold lower incidence of VEGFA gain in 
Golden Retrievers versus other breeds (22% versus 40%). These observations support prior 
transcriptional studies suggesting that the clinical heterogeneity of this cancer may reflect the 
existence of multiple, molecularly-distinct subtypes of canine hemangiosarcoma.
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INTRODUCTION
Canine hemangiosarcoma is a highly aggressive malignant neoplasm arising from cells 
involved in blood vessel formation, characterized by extensive clinical and anatomical 
heterogeneity, local invasiveness and a high incidence of local recurrence and metastatic 
disease. Hemangiosarcoma represents up to 7% of all malignant tumors of the domestic dog, 
translating to more than 50,000 new diagnoses in the US each year (Vail and MacEwen 
2000; Tamburini et al. 2009), most commonly arising in the spleen, right atrium, liver and 
subcutis. While cutaneous hemangiosarcoma has a relatively favorable prognosis, intra-
abdominal masses frequently remain undetected until presentation as acute, late-stage 
disease with extensive necrosis, coagulopathies and untreatable internal hemorrhage 
secondary to rupture of the tumor. In the most common splenic form, median survival is 
typically shorter than six months with standard-of-care surgical resection and intensive 
chemotherapy (reviewed in Bergman 2010).
Improved strategies for early detection and effective clinical management are an acutely 
high priority for those breeds that are highly predisposed to visceral hemangiosarcoma. 
Represented among these are several of the most popular family owned pure breeds, 
including the Golden Retriever, Labrador Retriever and German Shepherd Dog (Schultheiss 
2004; Thamm 2007; Bergman 2010; American Kennel Club 2012). These breeds also are 
among the ten most common contributors to the genetic ancestry of mixed-breed dogs, 
which themselves account for 53% of all family owned pet dogs within the US (Mars 
Veterinary 2011). Consequently, advances in clinical management of hemangiosarcoma may 
have tremendous impact across the full breadth of the pet dog population. The strong 
association between genetic background and hemangiosarcoma susceptibility suggests the 
presence of breed-associated heritable risk factors and molecular signatures reflecting 
biologically significant characteristics of their underlying pathogenesis. The lifetime risk for 
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hemangiosarcoma in the Golden Retriever (GR) is remarkably high, with estimates of 
greater than one in five (Glickman et al. 2000; Schultheiss 2004; Shearin and Ostrander 
2010). The genetic history of this breed is well documented (American Kennel Club 2006), 
and for over 30 years the GR has constituted one of the five most popular family-owned 
breeds in the US, yielding an estimated 50,000 new American Kennel Club registrations 
each year (American Kennel Club 2012). The GR therefore offers a comprehensive resource 
of naturally occurring clinical specimens and epidemiologic data in a population with 
restricted heterogeneity and well-defined ancestry, conferring vast potential for identifying 
tumor-associated risk factors and therapeutic targets for hemangiosarcoma.
Prior studies have described tumor-associated disruption of global transcriptional profiles in 
canine hemangiosarcoma, and gene-inactivating sequence mutations of key pathways 
associated with angiogenesis (Dickerson et al. 2005; Tamburini et al. 2009; Tamburini et al. 
2010). Germline risk factors are now being recognized that may explain the elevated 
susceptibility of the purebred GR population to this disease (Tonomura et al. submitted). To 
date, however, there remains no published knowledge of global somatic genome instability 
in the form of gene dosage imbalance in this cancer as a potential mechanism for 
transcriptional dysregulation. We used oligonucleotide array comparative genomic 
hybridization (oaCGH) analysis to develop the first description of the landscape of non-
random tumor-associated DNA copy number aberrations (CNAs) within primary visceral 
hemangiosarcoma. We explored the diversity of CNA profiles within and between 
genetically distinct populations through parallel evaluation of 40 GR tumors and 35 tumors 
from four additional breeds that exhibit an elevated incidence of this disease (Australian 
Shepherd Dog [ASD], Bernese Mountain Dog [BMD], Flat Coated Retriever [FCR] and 
German Shepherd Dog [GSD]). In combination these findings identify the subset of somatic 
hemangiosarcoma-associated CNAs that are shared across breeds, defining genomic 
intervals and genes that may play a fundamental role in disease pathogenesis and/or 
represent effective therapeutic targets. Additionally, we highlight breed-associated signatures 
consistent with differential gene dosage effects involving signaling pathways that are 
intimately involved in angiogenesis. Finally we draw comparisons with recently reported 
profiles of chromosomal instability in angiosarcoma (Italiano et al. 2012b), a rare and 
understudied human counterpart for which advances in clinical management may be aided 
greatly by the availability of a pertinent canine model.
MATERIALS AND METHODS
Case recruitment and histological evaluation
Clinical specimens of primary visceral hemangiosarcoma were acquired from family-owned 
dogs between 2003 and 2012 from community or institutional veterinary practices 
distributed broadly across the continental USA, during routine diagnostic procedures, under 
approved institutional protocols and with informed client consent. Representative biopsies 
were formalin-fixed and paraffin-embedded (FFPE) for histological evaluation. A diagnosis 
of hemangiosarcoma was confirmed by examination of hematoxylin and eosin (H&E)-
stained sections. All histological specimens were reviewed independently by two or more 
board-certified veterinary pathologists, one of whom (LB) was common to all cases. 
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Consecutive 25μm sections from each hemangiosarcoma tissue block were macrodissected 
to eliminate gross regions of healthy tissue by reference to the corresponding H&E slide, 
using dedicated equipment for each case to prevent cross-contamination. Tumor DNA was 
isolated from the fixed tissue sections using a QIAamp DNA FFPE Tissue Kit (Qiagen, 
Valencia, CA) for use in oaCGH analysis. FFPE tissue processing (based on the 
recommendations of van Essen and Ylstra (2012)) included an extended treatment with 
Qiagen Proteinase K (four days at 56°C) and a one hour incubation in a guanidine 
hydrochloride -based lysis buffer (Qiagen Buffer ATL) at 90°C. These procedures aid 
removal of DNA-protein cross-links created during formalin fixation, yielding DNA 
templates suitable for high-resolution, dual-channel Agilent oaCGH platforms without need 
for amplification or further fragmentation (Krijgsman et al. 2012; supplementary figure 1).
Identification of tumor-associated DNA copy number aberrations
oaCGH analysis was performed as described previously (Thomas et al. 2011) using a 
~180,000-feature microarray (Agilent Technologies, Santa Clara, CA) comprising repeat-
masked ~60-mer oligonucleotides distributed at approximately 13kb intervals throughout the 
dog genome sequence assembly (canFam version 2.0, May 2005, Lindblad-Toh et al. 2005). 
To maximize continuity and aid data integration, tumor DNA from each case was hybridized 
against common reference DNA samples comprising equimolar quantities of constitutional 
DNA from 10 clinical healthy GRs of the same gender as the patient. Array image files were 
processed using Feature Extraction version 10.10 and Genomic Workbench version 7 
(Agilent Technologies, Santa Clara, CA) and were then imported into Nexus Copy Number 
version 7 (Biodiscovery, El Segundo, CA). Raw data were filtered to exclude probes 
exhibiting non-uniform hybridization or signal saturation. Recurrent CNAs within each 
tumor were defined using the FASST2 segmentation algorithm in Nexus Copy Number, 
based on a minimum of three consecutive probes with log2 tumor:reference values ≥ 0.201 
(copy number gain) or ≤ −0.234 (copy number loss), resulting in an effective resolution of 
~26kb (two intervals of ~13kb). High amplitude gains and losses within individual tumors 
were defined using default log2 tumor: reference values of ≥1.14 and ≤−1.1, respectively.
oaCGH data for all cases were compiled using a threshold of 20% penetrance of the cohort 
to define the broadest regions of recurrent genomic imbalance. Genes and uncharacterized 
coding sequences within recurrent CNAs were defined using the UCSC canine genome 
sequence browser (http://genome.ucsc.edu/) and the Gene database at www.ncbi.nlm.gov/
gene. These data were filtered to flag regions of known natural copy number polymorphism 
defined by prior studies (Chen et al. 2009; Nicholas et al. 2009). Significant differences 
between pairwise comparisons of discrete subpopulations were defined as regions exhibiting 
≥20% relative difference in CNA frequency with p-values < 0.05 based on a two-tailed 
Fisher’s Exact test. The ‘comparisons’ tool of Nexus was used to identify breed-associated 
aberrations by sequential comparison of genome-wide CNA penetrance in each breed 
against the mean CNA penetrance for all other breeds. The GISTIC algorithm (Beroukhim et 
al. 2007) was then used to identify genomic regions for which the frequency and magnitude 
of genomic gain and loss was significantly increased relative to the ‘background’ level, 
indicating CNAs that are unlikely to occur by chance alone (G score < 0.05). Benjamini-
Hochberg false discovery rate (FDR) correction for multiple testing was applied (Benjamini 
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and Hochberg 1995), yielding a peak region of highest significance with minimum Q-bound 
value, flanked by a broader region with lower significance.
Discrete genomic regions are herein denoted according to their cytogenetic location and then 
their Mb position on that chromosome, based on the canFam v2.0 (Lindblad-Toh et al. 2005) 
dog genome sequence assembly. The absence of data for the dog Y chromosome in the 
female dog genome sequence assembly precluded the inclusion of data analysis for this 
chromosome.
Targeted fluorescence in situ hybridization analysis
Cases exhibiting discrete high level amplifications of the vascular endothelial growth factor 
A gene (VEGFA) in oaCGH were evaluated further by targeted fluorescence in situ 
hybridization (FISH) analysis. FISH analysis was performed using bacterial artificial 
chromosome (BAC) clones from the CHORI-82 canine BAC library (http://bacpac.chori.org, 
BACPAC Resources, Children’s Hospital Oakland Research Institute, Oakland, CA), 
containing the full coding sequence of the VEGFA gene (clone 152L05) and associated 
receptor (VEGFR2/KDR, clone 34E11). FISH probes for VEGFA and VEGFR2/KDR were 
generated by incorporation of fluorescent-conjugated nucleotides into BAC DNA using nick 
translation, and their unique chromosomal location was verified by conventional FISH 
analysis of chromosome preparations from clinically healthy dogs (Breen et al. 2004). Thin 
(5 micron) sections from FFPE tissue blocks were floated onto positively charged slides and 
deparaffinised with xylene. Specimens were then exposed to one hour enzymatic treatments 
at 37°C with hyaluronidase type VIII (45 U/μl in 250mM TRIS-buffered saline, pH7.4, 
Sigma-Aldrich, St. Louis, MO) followed by collagenase (236U/μl each of collagenases I and 
II, and 0.4U/μl of collagenase III [Invitrogen/Life Technologies. Carlsbad, CA] in Hank’s 
Balanced Salt Solution supplemented with 2.4μM CaCl2). Specimens were then exposed to 
Abbott VP2000 Pre-Treatment Reagent (Abbott Laboratories, Chicago, IL) for one hour at 
80°C, and then subjected to further digestion for one hour with Abbott Protease II Solution 
at 37°C. Labeled probes (100ng each) were combined with 25μg of sonicated dog total 
genomic DNA and applied to processed FFPE sections and denatured in situ at 80°C for five 
minutes. Hybridization was performed for 16 hours at 38°C, followed by a two minute wash 
in 0.4× saline-sodium citrate buffer (SSC)/0.3% IGEPAL (pH7) at 73°C and a one minute 
wash in 2 × SSC/0.1% IGEPAL (pH7) at ambient temperature. Image analysis was 
performed as described previously (Breen et al. 2004), using incremental capture (Smart 
Capture 3, Digital Scientific, Cambridge UK) of successive vertical planes to permit 
visualization of probe signals throughout the three-dimensional depth of each cell.
RESULTS
Genome-wide profiles of recurrent CNAs in canine hemangiosarcoma
The cohort of 75 hemangiosarcomas exhibited limited global DNA copy number instability, 
ranging from low amplitude imbalances of large chromosomal regions and entire 
chromosomes to infrequent, high amplitude aberrations of focal subchromosomal regions 
suggestive of structural rearrangement. A genome-wide penetrance plot of the frequency and 
relative distribution of CNAs within the cohort indicated that the global incidence of any 
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single CNA was low (Figure 1a). Of 317 discrete CNAs that were classed as recurrent 
(shared by ≥ 20% of cases), none were common to more than 45% of the cohort, and only 
ten were evident in ≥ 25% of cases (Supplementary Table 1). These 317 regions (164 gains 
and 153 losses) ranged in length from 4.5kb to 19.6Mb, but were heavily skewed toward 
small intervals (mean 654kb, median 241kb), with the vast majority (88%, 278/317 regions) 
smaller than 1Mb in size. Of the 317 recurrent CNAs, 125 overlap with natural copy number 
variants (CNVs) identified in prior surveys of healthy dogs (Chen et al. 2009; Nicholas et al. 
2009), including all ten CNAs that were common to more than 25% of hemangiosarcoma 
cases. No recurrent high-level copy number amplifications or apparent homozygous 
deletions were detected within the cohort of 75 cases.
The most physical extensive CNAs present in ≥ 20% of the cohort were copy number gain 
along the full length of dog chromosomes 13 (CFA13), 24 and 31, and loss of CFA16 
(Figure 1a). These events resulted in concomitant copy number imbalance of several cancer-
associated genes with distinct biological relevance to hemangiosarcoma. Three such genes 
lie consecutively within a 754kb region of CFA13, namely the platelet-derived growth factor 
receptor gene PDGFRA (CFA13q21.3:49.7Mb, gained in 20% of cases), the KIT oncogene 
(CFA13q21.3:50.1Mb, gained in 27% of cases) and the KDR receptor tyrosine kinase gene 
(also known as FLK1/VEGFR2, CFA13q21.3:50.3Mb, gained in 28% of cases). The 
angiopoetin 1 gene ANGPT1, located proximally at CFA13q12.1:11.2Mb, was gained in 
20% of cases. Additional members of the angiopoetin family were also contained within 
recurrent CNAs, specifically angiopoetin 2 (ANGPT2, CFA16q25.2:61.4Mb, 20% loss) and 
angiopoetin 4 (ANGPT4, CFA24q21:23.0Mb, 31% gain), and the angiopoetin-like 6 gene 
(ANGPTL6, CFA20q16:54Mb, 24% gain). A distinct peak of recurrent gain was evident on 
CFA12q13, corresponding to increased copy number of the vascular endothelial growth 
factor gene VEGFA (CFA12q13:15.2Mb) in 29% of cases, of which four cases (5% of the 
cohort) were consistent with a high level amplification. oaCGH detected deletion of the 
CDKN2A/B tumor suppressor gene region (CFA11q16:44.3Mb) in 28% of cases, while the 
CDKN2A interacting protein gene CDKN2AIP (CFA16q24:49.9) was deleted in 20% of 
cases. CNAs of other well-described tumor associated genes including PDGFRB 
(CFA4q32), TP53 (CFA5q22), MYC (CFA13q13) and PTEN (CFA26q25) were not 
recurrent, occurring with < 20% penetrance within the cohort.
These data were interrogated further using GISTIC analysis to distinguish CNAs containing 
candidate genes as potential drivers of tumor pathogenesis from the background of 
generalized ‘passenger’ aberrations occurring at random. GISTIC identified 89 discrete 
CNAs whose amplitude and relative distribution indicated they were significantly unlikely to 
occur by chance alone (30 gains and 59 losses, G-score > 1.0, Q-bound value < 0.05, Figure 
1b and Supplementary table 2). The broad genomic distribution of these regions suggests 
that the extensive recurrent gains of CFA13, 24 and 31, and losses of CFA16, are more 
consistent with passenger rather than driver aberrations. Of the 16 regions identified by 
GISTIC that share no apparent overlap with known natural CNVs, the most significant was a 
region on CFA12q13:15.1Mb that flanks the VEGFA gene (CFA12q13:15.2Mb, G-score = 
13.9, Q-bound score = 5.83×10−7). The second most significant (G-score = 13.6, Q-bound 
score = 2.44×10−5) was deletion of a region on CFA11q16:44,3Mb that contains the MTAP, 
CDKN2A and CDKN2B loci, with the peak of significance localized at the CDKN2A locus. 
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Also of note was a significant peak of gain on CFA5q32:60Mb (G-score = 10.9, Q-bound 
score = 1.48×10−5), detected in 21% of cases, which coincides with the SKI gene (v-ski 
sarcoma viral oncogene homolog). The combination of their penetrance in the population, 
accompanied by their significantly non-random relative distribution and amplitude and their 
biological function, supports the intimate association of disrupted dosage of VEGFA, 
CDKN2A and SKI genes with the disease phenotype.
FISH analysis of cases exhibiting high level amplification of VEGFA showed extensive 
heterogeneity in the number and distribution of VEGFA and VEGFR2/KDR probe signals 
within histological confirmed regions of tumor. The VEGFA probe frequently showed 
clusters of intense fluorescent signal suggestive of tandem duplication, while the 
VEGFR2/KDR probe showed only modest increase in copy number in cases showing gain 
of this region in oaCGH (Figure 2). Aberrant cells were typically interspersed with pockets 
of cells with grossly normal copy number, indicative of a highly heterogeneous cell 
population.
Comparison of CNA profiles in GRs with other breeds
oaCGH data were subcategorized by breed as either ‘GR’ (n = 40) or ‘other’ (n = 35) for 
initial assessment of evidence for breed-associated CNAs. This analysis demonstrated that 
global CNA profiles were broadly conserved in both groups as generalized characteristics of 
hemangiosarcoma, including gains of CFA13, 24 and 31, and loss of CFA16 (Figure 3a). 
The relative distribution of these CNAs showed subregional variation; for example, GRs 
exhibited recurrent deletion along the full length of CFA16, while in other breeds this was 
restricted primarily to the distal 75% of this chromosome. Similarly, while GR cases showed 
broad gain along both CFA20 and 31, in other breeds this was restricted to the distal 25% of 
these chromosomes. The peak in incidence of gain on CFA24 was proximal in GR cases 
(located at ~16Mb) versus distal in other breeds (~39Mb). Furthermore, the peak of 
recurrent gain on CFA12 around the VEGFA gene was diminished by almost half in GR 
cases (22% of cases) compared to those of other breeds (40%). Annotated below the CNA 
penetrance plots in figure 3a are the 188 discrete regions of significant difference between 
the two categories (Supplementary Table 3). Of these 188 regions, 50 coincide with known 
natural canine copy number variants (CNVs, and none overlap with cancer-associated genes 
shown to be involved in recurrent CNAs within the full cohort of 75 cases. The majority of 
these regions represented small genomic intervals (mean = 221kb, with 181/188 regions 
<1Mb in size and the remaining seven regions <2.4Mb in size) and were distributed widely 
throughout the genome. Figure 3a shows, however, that the incidence of CFA31 gain was 
significantly elevated in GRs within the region spanning CFA31q11-q15.1 (4.3–28.4Mb), 
reaching a maximum of 45% of GRs versus 20% of other breeds. An additional cluster of 
significant regions reflected the increased incidence of deletion on CFA16qprox in GRs 
versus other breeds.
Assessment of breed-associated CNA profiles
Similar principles were then applied to genome-wide CNA profiles of the ‘other breeds’ 
category, by examination of the oaCGH data contributed by each of the four component 
breeds (Figure 3b). The most remarkable differences were evident from comparison of ASD 
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tumors against all other cases. Hemangiosarcoma cases of this breed showed significantly 
elevated gain of both CFA24 (including ANGPT4) and 35, and loss of CFA33 and 37. Partial 
deletion of the distal half of CFA16 (including the CDKN2A-interacting protein 
CDKN2AIP), and gain of CFA31qdist (including the transcription factor gene RUNX1) and 
subregions of CFA13 (including KIT, KDR and PDGFRA), were also significantly elevated 
in this breed. Interestingly ASD cases exhibited significantly increased incidence of gain 
both of the platelet-derived growth factor gene PDGFA (CFA6q15, 30% of cases) and of the 
receptor tyrosine kinase gene PDGFRA (CFA13q21.3, 50% of cases), relative to other 
breeds. The incidence of PDGFA gain was also significantly elevated in the GSD, along with 
subregional gain along CFA6qprox and CFA20qdist, and partial deletions of CFA7 and 38. 
FCR cases exhibited a significant peak of gain flanking VEGFA on CFA12q13. While BMD 
cases also showed significantly elevated CFA12qprox gain, this region was located ~4Mb 
proximal to the VEGFA locus; however these cases showed a significant association with 
deletion of CFA5qprox and gain of CFA36qdist. Figure 4 summarizes the CNA frequencies 
for genes discussed in the text both within the full cohort and in each breed, and additional 
details are provided in Supplementary Table 4.
DISCUSSION
Genome-wide profiles of copy number imbalance in canine hemangiosarcoma
Somatic DNA copy number profiling of 75 canine hemangiosarcomas revealed no highly 
recurrent CNA signatures that might be considered hallmarks of this cancer. Rather, 
hemangiosarcoma exhibits a relatively low level of global CNA compared to the extensive 
aneuploidy evident in other canine sarcomas evaluated using similar techniques (Angstadt et 
al. 2011; Hedan et al. 2011; Thomas et al. 2011), with remarkably few aberrations exceeding 
20% penetrance. This is likely a consequence of the high degree of cellular heterogeneity 
associated with hemangiosarcoma, which was evident from FISH analysis in the form of 
discrete pockets of tumor interspersed with extensive regions of grossly normal stromal 
tissue. Targeted FISH analysis of high-level amplification events also demonstrated 
substantial cell-to-cell variation in both probe copy number and distribution within 
individual cases, suggestive of variable, complex structural rearrangement through multiple 
rounds of chromosome breakage and fusion, as is typical of solid tumors (for example, 
Thompson and Compton 2011).
Despite macrodissection of fixed tissue specimens to enrich for malignant cell populations it 
is highly likely that residual microscopic heterogeneity would result in attenuation of CNA 
penetrance due to contaminating stromal DNA. The variable degree of aneuploidy apparent 
between individual cases may be associated in part with differential progression rates and 
stromal involvement; however, the extensive range in the number and distribution of CNAs 
evident within the cohort, despite their histomorphologic characteristics, supports prior 
transcriptional studies suggesting the existence of several related but molecularly distinct 
forms of hemangiosarcoma (Dickerson et al. 2005; Tamburini et al. 2009; Tamburini et al. 
2010).
Recurrent imbalance of extensive genomic regions in hemangiosarcoma was restricted 
primarily to gain of CFA13, 24 and 31, and loss of CFA16. Increased copy number of 
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CFA13 is recurrent in a diverse range of canine cancers, including non-Hodgkin’s 
lymphoma, appendicular osteosarcoma, leukemia, glioma and histiocytic sarcoma (Thomas 
et al. 2009; Angstadt et al. 2011;Becker et al. 2011;Hedan et al. 2011; Thomas et al. 2011). 
Similarly, the incidence of CFA31 gain in hemangiosarcoma was comparable to that of a 
broad range of canine cancers studied to date, including appendicular osteosarcoma (20–
35% of cases) (Angstadt et al. 2012; Karlsson et al. in press), glioma (35% of cases) 
(Thomas et al. 2009) and B-cell non-Hodgkins lymphoma (~20% of cases) (Thomas et al. 
2011). The present data therefore add to evidence that gains of CFA31, and of CFA13 in 
particular, both represent generalized CNAs rather than hallmarks of specific tumor 
subtypes. CFA24 gain is less widely evident in prior reports of canine cancers, but occurs in 
hemangiosarcoma at similar frequency to that of appendicular osteosarcoma (30–45% of 
cases, Angstadt et al. 2012; Karlsson et al. in press), histiocytic sarcoma (20–30% of cases, 
Hedan et al. 2011) and glioma (~30% of cases, Thomas et al. 2009). In contrast, among 
published studies to date, recurrent loss of CFA16 has been reported only in histiocytic 
sarcoma (~70% of cases, Hedan et al. 2011), T-cell non-Hodgkins lymphoma (~20% of 
cases, Thomas et al. 2011) and appendicular osteosarcoma (50–70% of cases, Angstadt et al. 
2012; Karlsson et al. in press), suggesting that this CNA may be a characteristic of the 
broader category of solid tumors defined as sarcomas.
GISTIC analysis revealed a significant peak of deletion in hemangiosarcoma on CFA11q16 
encompassing CDKN2A/B and MTAP, with maximum significance coinciding with the 
CDKN2A gene, highlighting this locus as a potential driver of tumor development. Several 
additional dog cancers with recurrent CFA11 deletion also show a focal peak in penetrance 
at CFA11q16, similarly indicative of a fundamental role for this locus in tumor pathogenesis 
(for example, T-cell non-Hodgkins lymphoma (Thomas et al. 2011), appendicular 
osteosarcoma (Angstadt et al. 2012; Karlsson et al. in press) and histiocytic sarcoma (Hedan 
et al. 2011). Like hemangiosarcoma, canine histiocytic sarcoma is a highly aggressive and 
locally invasive cancer with rapidly fatal clinical course, frequently manifesting in a 
disseminated form with multiple organ involvement, and with a strong breed predilection. 
Interestingly the MTAP and CDKN2A/B region at CFA11q16 lies within the major germline 
risk haplotype for histiocytic sarcoma in the BMD (Shearin et al. 2012). Furthermore, a 
germline risk haplotype for appendicular osteosarcoma has now been mapped to the same 
region in the Greyhound (Karlsson et al. in press). This direct association between germline 
risk and somatic aberration provides strong support for the fundamental involvement of 
MTAP and/or CDKN2A/B dysregulation as a driver of these disease phenotypes. 
Interestingly, however, despite recurrent deletion of the CFA11q16 locus in 
hemangiosarcoma (28% of all cases, and 30% of all GRs), a recent genome-wide association 
study of germline risk factors in the GR (Tonomura et al. submitted) shows no significant 
overlap with somatic CNA. Although 21/75 hemangiosarcoma cases exhibited deletion of 
the CDKN2A/B region, only two cases were consistent with homozygous deletion. While 
this may be a consequence of stromal contamination, the relative peak in CNA penetrance at 
this site relative to its flanking regions was less distinct in hemangiosarcoma than in 
osteosarcoma, histiocytic sarcoma or T-cell lymphoma, in which homozygous deletion is 
frequent (Angstadt et al. 2012;Hedan et al. 2011; Thomas et al. 2011). This suggests that 
CFA11 may harbor other major gene targets for hemangiosarcoma pathogenesis. The 
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extension of these genome-wide association studies to additional purebred dog populations 
will reveal whether these risk haplotypes are more closely linked to the disease phenotype or 
to genetic ancestry. Moreover, many recurrent CNAs overlap with CNVs identified in prior 
studies of clinically healthy dogs (for example Chen et al. 2009; Nicholas et al. 2009). There 
is growing evidence for the involvement of these natural polymorphisms in a variety of 
human diseases, including cancer (for example, Fanciulli et al. 2010; Shlien and Malkin 
2010). CNVs are less well characterized in dogs, however, and thus at present there is 
insufficient evidence to permit any association between specific natural polymorphisms and 
the disease phenotype.
GISTIC also identified VEGFA as a likely target for the recurrent subregional gain on 
CFA12q13, consistent with prior transcriptional studies supporting the role of this growth 
factor and associated receptors in malignant proliferation of hemangiosarcoma (Yonemaru et 
al. 2007;Tamburini et al. 2009;Tamburini et al. 2010). A previous study (Yonemaru et al. 
2006) demonstrated elevated mRNA and protein expression of VEGFA and its receptors 
VEGFR1/Flt-1 and VEGFR2/Flk-1/KDR in malignant cells of hemangiosarcoma, compared 
to benign hemangioma. In the present study genomic gain of VEGFR2/Flk-1/KDR occurred 
in 28% of all cases, in contrast to VEGFR1/Flt-1 gain in only 8% of cases. This is consistent 
with the generalized description of the former as the major mediator of the angiogenic 
effects of VEGFA, although the distinction may be somewhat more complex (Tamburini et 
al. 2009). Aberrant upregulation of VEGFA in hemangiosarcoma has also been associated 
with the presence of inactivating point mutations and deletions within the PTEN tumor 
suppressor gene on CFA26q25, resulting in unregulated endothelial cell growth and 
angiogenesis (Dickerson et al. 2005). While PTEN deletion is highly recurrent in other dog 
sarcomas (Angstadt et al. 2011; Hedan et al. 2011; Thomas et al. 2011), only 5% of 
hemangiosarcoma cases (4/75) showed copy number loss of this locus, suggesting that 
genomic deletion does not constitute an alternative mechanism for loss of PTEN function in 
this disease. GISTIC analysis identified the SKI oncogene as a strong candidate for the 
target of the CFA5q32 gain in 21% of hemangiosarcoma cases. Upregulation of SKI, a 
negative regulator of the TGFβ signaling pathway, has been reported in a diverse range of 
human cancers, promoting tumor growth and induction of angiogenesis and conferring a 
negative prognosis (reviewed in Bonnon and Atanasoski 2012). Moreover, elevated SKI 
expression has been identified in human pediatric hemangiomas, with the strongest 
expression evident in the most actively proliferating of these benign endothelial cell tumors 
(O et al. 2009). Transcriptional regulation of the human SKI gene is not yet well understood, 
and the mechanism by which SKI dysregulation occurs in malignant cells is also unclear 
(Bonnon and Atanasoski 2012). To our knowledge there are no prior studies of the SKI gene 
in canine tumors, and definition of its potential relevance will therefore require focused 
attention in future investigations.
Assessment of differential CNA profiles in GR hemangiosarcoma
Subclassification of the cohort by breed permits the first insight into the relationship 
between somatic DNA copy number aberrations and genetic background in canine 
hemangiosarcoma. Comparison of all GR cases against those of the four other selected 
breeds showed that CNA profiles are broadly conserved between these subcategories, but 
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revealed that GRs exhibit significantly more frequent gain of CFA31 and subregional loss on 
CFA16qprox, as well as a contrasting profile of copy number increase on CFA24. Of 
particular note was the reduced incidence of VEGFA gain in GRs (22% of GRs versus 40% 
of cases from the four other breeds). Prior studies have indicated that transcriptional profiles 
of hemangiosarcoma in the GR are distinct from those of other breeds, highlighting 
differential involvement of members of the VEGF pathway. Tamburini et al. (2009) reported 
elevated mRNA and protein expression of VEGFR1/Flt-1 in GR hemangiosarcoma, not as a 
consequence of gross elevated gene expression but rather through enrichment of VEGFR1/
Flt-1 in conjunction with other functionally related signaling molecules. Targeted inhibition 
of VEGFR1/Flt-1 increased tumor proliferation in GR hemangiosarcoma, but was 
ineffective in other breeds. Conversely, immunohistochemical staining of hemangiosarcoma 
cell lines from non-GRs showed elevated VEGFR2/Flk-1/KDR expression compared to GR 
cells (Tamburini et al. 2009). These observations were not reinforced by significant 
differences in the DNA copy number profiles of either VEGF receptor when comparing GR 
tumors with other breeds in the present study. The identification of VEGFA as a potential 
driver of tumor development, coupled with the almost two-fold reduction in VEGFA gain in 
GR tumors and the highly variable incidence of both VEGFA and VEGFR2/Flk-1/KDR gain 
in other breeds, however, continues to highlight the fundamental relevance of this pathway. 
In recent years, critical advances in human medicine have yielded several monoclonal 
antibodies and tyrosine kinase inhibitors of the VEGF pathway, with others showing 
promise in clinical trials (Saharinen et al. 2011). Of particular note, a recent phase II trial 
showed bevacizumab, a recombinant humanized antibody against VEGF, to be safe and 
effective for the treatment of angiosarcoma (Agulnik et al. 2012). The increasing volume of 
evidence for an intimate association between hemangiosarcoma pathogenesis and the VEGF 
pathway reinforces the urgency for further investigation of therapeutic options in veterinary 
medicine, and raises the possibility for breed-associated strategies for clinical management.
Emerging evidence for breed-associated CNA profiles in hemangiosarcoma
The inclusion of cases from four non-GR breeds enables the first glimpse into the 
relationship between genetic ancestry and somatic DNA copy number imbalance in 
hemangiosarcoma. FCR cases showed the most compelling evidence for intimate association 
between VEGFA copy number gain and tumor pathogenesis, but were otherwise globally 
consistent with observations across the entire cohort. Significantly elevated CFA20qdist gain 
was revealed in GSD cases, while BMD cases exhibited elevated CFA5 imbalance. ASD 
cases demonstrated the most complex aberration profiles, with a series of marked deviations 
away from the global penetrance profiles of the full cohort. The global recurrence of CFA16 
deletions and gains of CFA24 shown in figure 1a are strongly driven by the ASD, which in 
turn exhibits significantly elevated incidence of several genes that are fundamental to tumor 
pathogenesis (Figure 4). Among these are members of the angiopoietin gene family, which 
are central to the regulation of angiogenesis, endothelial cell survival, proliferation and 
migration, and which have been implicated in angiosarcoma development in human patients 
(Brown et al. 2000), The products of the ANGPT1 (CFA13q12.1) and ANGPT4 
(CFA24q21) genes act as ligands for the angiopoetin tyrosine kinase receptor Tie2, which is 
expressed on vascular endothelium, promoting endothelial cell survival and proliferation and 
blood vessel stability. Conversely, the ANGPT2 gene product (CFA16q25.2) generally acts 
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as an antagonist, promoting endothelial cell death and regression of blood vessels (Cascone 
and Heymach 2012). It is interesting to note, therefore, that the pro-angiogenic factors 
ANGPT1 and 4 each lie on chromosomes exhibiting recurrent genomic gain in 
hemangiosarcoma (CFA13 and 24), with a significantly increased incidence of ANGPT4 in 
the ASD (70% of ASD cases versus a mean of 31% in other breeds). In contrast, the 
typically anti-angiogenic ANGPT2 ligand lies on CFA16, the chromosome with highest 
incidence of global deletion, but showed a low incidence of copy number loss across the 
cohort (20% of all cases). Promising results are now emerging using various inhibitory 
factors for regulation of angiopoetins in a wide range of human cancers (Cascone and 
Heymach 2012). The results of the present study suggest that these principles may be 
applicable to hemangiosarcoma, potentially with breed-associated efficacy. Despite global 
conservation in their CNA profiles there is, therefore, emerging evidence also for additional 
breed-associated CNAs in hemangiosarcoma outwith the GR.
Canine hemangiosarcoma as a potential model for human angiosarcoma
Several reports have proposed hemangiosarcoma as a naturally occurring model of human 
angiosarcoma, principally based on commonalities in their clinicopathologic features (for 
example, Tamburini et al. 2010;Andersen et al. 2013;Dickerson et al. 2013). Angiosarcoma, 
a highly vascular endothelial neoplasm, commonly arises de novo, but may also manifest as 
a secondary tumor subsequent to radiation therapy or in association with chronic 
lymphedema (for example Roy et al. 2004). Both forms share grossly comparable clinical 
behavior and histomorphology (Billings et al. 2004). As with canine hemangiosarcoma, 
options for effective clinical management of angiosarcoma are limited, and the prognosis is 
typically poor (~30% overall five-year survival (Fury et al. 2005). The genomic basis of 
angiosarcoma remains poorly understood, in large part due to its relative rarity, comprising 
just 1–2% of the ~10,500 new soft-tissue sarcoma cases reported each year in the US 
(Baumhoer et al. 2005; Antonescu et al. 2009; Jemal et al. 2010; Lahat et al. 2010). The 
relative rarity of angiosarcoma will inevitably restrict resources for evaluating the efficacy of 
novel therapeutic agents in human subjects and for clinically predictive patient stratification. 
The extensive repository of clinical materials and data associated with the high incidence of 
hemangiosarcoma in defined purebred dog populations could represent an opportunity to 
address limitations resulting from the infrequency of this cancer in human populations. This 
concept has been supported by several studies that demonstrate related tumor-associated 
transcriptional profiles and gene-inactivating sequence mutations of key pathways associated 
with angiogenesis in angiosarcoma and hemangiosarcoma, and commonalities in the 
potential involvement of specific micro-RNA elements (Dickerson et al. 2005; Dews et al. 
2006; Yonemaru et al. 2006; Yonemaru et al. 2007; Antonescu et al. 2009; Tamburini et al. 
2009; Sarver et al. 2010; Tamburini et al. 2010; Guo et al. 2011; Taylor et al. 2011; Italiano 
et al. 2012a; Italiano et al. 2012b). The findings of the present study afford the first 
opportunities to establish whether the similarities between angiosarcoma and 
hemangiosarcoma extend to their CNA profiles. Comparison of these canine data with 18 
angiosarcoma profiles generated using an oaCGH platform with comparable resolution 
(Italiano et al. 2012b) demonstrates that both tumors present with a relatively low degree of 
aneuploidy, with few individual CNAs exhibiting >20% penetrance. High-level amplification 
of the MYC locus on human chromosome 8q24.21:128.8Mb occurs in 50–60% of 
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angiosarcoma cases, representing one of few consensus chromosomal aberrations to be 
identified in this cancer. This CNA is associated with concomitant transcriptional 
upregulation of the MYC oncogene, resulting in downstream inhibition of angiogenesis 
(Dews et al. 2006; Manner et al. 2010; Guo et al. 2011; Italiano et al. 2012b). In the present 
study, increased copy number of MYC occurred in only 17% of canine hemangiosarcoma 
cases, and exceeded 20% penetrance in only two breeds, the ASD (30%) and BMD (33%). 
This event was associated almost exclusively with gain of a broad interval on CFA13, and 
only a single case exhibited high level focal MYC amplification. This may in part reflect the 
nature of the canine cohort as primary tumors, since MYC amplification has historically 
been regarded as a hallmark of secondary angiosarcoma (Manner et al. 2010; Guo et al. 
2011). A more recent, high-resolution oaCGH study has since demonstrated that MYC 
amplification is also recurrent in de novo human angiosarcoma, and revealed significant 
conservation of genomic profiles in primary and secondary cases, blurring their distinction at 
a molecular level (Italiano et al. 2012b). Aside from lack of conservation in MYC copy 
number status, global comparison of data from the present study with human angiosarcoma 
data from (Italiano et al. 2012b) indicates negligible overlap in their CNA profiles. It seems 
likely that the apparent contrast in the molecular characteristics of hemangiosarcoma and 
angiosarcoma may be driven by the relative anatomical distribution of tumors in these 
populations. Angiosarcoma arises in a variety of skin, soft tissue or visceral locations but 
occurs most commonly as a cutaneous lesion (Lucas 2009) while the majority of canine 
cases manifest in the abdominal or thoracic cavities (Bergman 2010). The 18 angiosarcoma 
cases evaluated by Italiano et al. (2012b) represent a combination of both cutaneous and 
soft-tissue tumors from a broad range of anatomical locations, which precludes the ability to 
perform more focused comparisons with canine genomic data. Comparisons of 
histopathologic morphology showed that the visceral hemangiosarcoma specimens in the 
present study were grossly indistinguishable from human anaplastic angiosarcoma arising 
from non-cutaneous sites, while angiosarcoma arising from the skin or breast parenchyma 
typically exhibited more well-differentiated features (Italiano et al. 2012b). It is therefore 
possible that greater cross-species conservation in CNA profiles will be evident through 
comparison of canine cutaneous hemangiosarcoma with human angiosarcoma. Cutaneous 
hemangiosarcoma lesions, while globally infrequent, are prevalent in several dog breeds 
with short hair and limited or variable skin pigmentation, such as the Whippet and 
Dalmation (Hargis et al. 1992; Schultheiss 2004). The extension of cytogenomic studies to 
cases from these breeds will clarify the influence of genetic background on molecular 
profiles in hemangiosarcoma. In the meantime, the results of the present study indicate the 
need for more extensive assessment of the global validity of the canine system as a relevant 
model for human angiosarcoma biology.
Conclusion
Visceral hemangiosarcoma constitutes a tremendous challenge for veterinary practitioners 
due to its aggressive and rapid clinical course, limited treatment options and heterogeneity in 
anatomical location and intratumoral histomorphology. Through genomic profiling of 75 
primary cases we demonstrate that the clinicopathologic heterogeneity of canine 
hemangiosarcoma is recapitulated by extensive variation in the distribution of non-random 
somatic DNA copy number aberrations, both within and between individuals and distinct 
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genetic populations. These data reveal recurrent gene dosage imbalances with direct 
biological relevance to tumor pathogenesis that offer potential for therapeutic modulation of 
discrete pathways involved in tumor development. This in turn provides the first opportunity 
for comparative assessment of genome-wide somatic DNA copy number aberrations in 
canine hemangiosarcoma and clinicopathologically similar human angiosarcoma. Both 
present with limited aneuploidy but there is little conservation in their genomic profiles, 
indicating the need for further assessment of the relevance of the dog as a model for the 
human disease. Our findings provide an insight into the relationship between somatic DNA 
copy number profiles and genetic ancestry through parallel evaluation of cases from five dog 
breeds with elevated predisposition to hemangiosarcoma. The high degree of intra- and 
intertumoral heterogeneity in CNA profiles indicates a need for extension to larger cohorts 
and additional breeds for refining evidence for the existence of discrete molecular subtypes.
These findings contribute toward an expanding catalogue of complementary genomic 
resources directed towards improved strategies for early detection and effective clinical 
management of canine hemangiosarcoma, which will also aid comprehension of its 
underlying pathogenesis and validity as a model for human angiosarcoma.
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ABBREVIATIONS
ASD Australian Shepherd Dog
BAC bacterial artificial chromosome
BMD Bernese Mountain Dog
CFA Canis familiaris
CNA copy number aberration
CNV copy number variant
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FISH fluorescence in situ hybridization
GR Golden Retriever
GSD German Shepherd Dog
H&E hematoxylin and eosin
oaCGH oligonucleotide array comparative genomic hybridization
SSC saline-sodium citrate
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A) Penetrance plot of recurrent CNAs identified within the cohort of 75 hemangiosarcoma 
cases. Genomic locations are plotted along the x-axis. The y-axis indicates the percentage of 
the corresponding cohort that demonstrated either copy number gain (shown in blue above 
the midline) or loss (shown in red below the midline) of the corresponding chromosome 
region. The horizontal bars immediately above and below the midline indicate the 20% 
cutoff used to define recurrent CNAs. B) GISTIC analysis of CGH profiles from all 75 cases 
identified 89 discrete CNAs whose amplitude and relative distribution was significantly 
increased above background levels (G-score > 1.0, Q-bound > 0.05). The peak region of 
significance is highlighted in dark grey, flanked by a broader region of reduced significance 
shown in pale grey. Genomic locations are plotted along the x-axis, and G-scores for 
statistical significance are shown on the y-axis (larger bars indicate higher significance).
Thomas et al. Page 19














Hemangiosarcoma cases exhibited VEGFA amplification detected by oaCGH and FISH. A) 
Genome-wide oaCGH profiles for each of four cases with VEGFA amplification (denoted i 
through iv) demonstrating the extensive variation in the number, size and distribution of 
CNAs between cases, which are indicated by horizontal lines above (gain) or below (loss) 
the midline. The chromosomal locations of the VEGFA and VEGFR2/KDR genes are 
indicated by yellow and red arrows, respectively. All four cases show a discrete 
amplification at the VEGFA locus on CFA12q13. The VEGFR2/KDR locus is balanced in 
all cases except case [iv], which shows a low-amplitude copy number gain. Case [iii] 
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exhibited the sole example of MYC amplification, evident as the spike of high amplitude 
copy number increase on CFA13q13, proximal to the VEGFR2/KDR locus. B) Enlarged 
view of the CGH profile of CFA12 in each case, indicating VEGFA amplification (dotted 
line). Additional disruption in copy number along the length of the chromosome is 
suggestive of multiple structural rearrangements. C) FISH analysis revealed clusters of probe 
signal consistent with tandem duplication of the VEGFA locus (yellow signal). The number 
and distribution of VEGFA probe signals varied even within the same field of view, 
indicative of extensive heterogeneity in cell populations and stromal contamination. FISH 
analysis of VEGFR2/KDR (red signal) was grossly normal in all but case [iv, pictured], 
which showed a minor increase in copy number consistent with oaCGH analysis.
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A) Penetrance plot of recurrent CNAs in GR hemangiosarcoma (n = 40) compared with 
‘other breeds’ (n = 35). Comparison of these data identifies discrete regions of significant 
difference in their CNA profiles. These regions are denoted by red or blue bars below the 
upper panel that shows the relative difference in CNA frequency between the two groups. B) 
CNA penetrance plots of each non-GR breed group, annotated to show regions of 
significantly different CNA identified within each breed when compared sequentially against 
the mean penetrance within all other cases. The highly penetrant gain on CFA8 coincides 
with the dog T cell receptor alpha chain immunoglobulin domain, and is evident as an 
apparent CNA due to the rearrangement of this region in the blood-derived reference DNA.
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Forest plot summarizing penetrance data for genes involved in recurrent CNAs identified 
within the cohort of 75 hemangiosarcoma cases, and within each breed. Genes described in 
the text are ordered on the vertical axis according to their physical location in the dog 
genome. The frequency of gain and loss of each locus in each breed is shown on the 
horizontal axis as a percentage of that population, in addition to the frequency in the entire 
cohort. Asterisks indicate CNA penetrance values that deviate significantly in one breed 
compared to all other breeds (Fishers Exact test, p < 0.05).
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